

## Innovations in drug delivery systems: A review of the pharmacist's role in enhancing efficacy and patient compliance

Obe Destiny Balogun <sup>1, \*</sup>, Oluwatoyin Ayo-Farai <sup>2</sup>, Oluwatosin Ogundairo <sup>3</sup>, Chinedu Paschal Maduka <sup>4</sup>, Chiamaka Chinaemelum Okongwu <sup>5</sup>, Abdurraheem Olaide Babarinde <sup>6</sup> and Olamide Tolulope Sodamide <sup>7</sup>

<sup>1</sup> Independent Researcher, Lima Ohio, USA.

<sup>2</sup> Jiann-Ping Hsu College of Public Health, Georgia Southern University, Georgia.

<sup>3</sup> Independent Researcher, USA.

<sup>4</sup> Institute of Human Virology, Nigeria.

<sup>5</sup> Department of Community Health and Primary Care, University of Lagos, Nigeria.

<sup>6</sup> The Heller School for Social Policy and Management, Brandeis University, Waltham Massachusetts.

<sup>7</sup> Africa Voices HQ, Nigeria.

World Journal of Advanced Research and Reviews, 2023, 20(03), 1268–1282

Publication history: Received on 06 November 2023; revised on 16 December 2023; accepted on 19 December 2023

Article DOI: <https://doi.org/10.30574/wjarr.2023.20.3.2587>

### Abstract

This review explores the dynamic landscape of drug delivery systems, focusing on their profound impact on therapeutic efficacy and patient compliance. The integration of nanotechnology, RNA therapeutics, implantable devices, 3D printing, and artificial intelligence heralds a transformative era in precision medicine. Nanoparticles enable precise targeting, while RNA therapeutics offer molecular-level interventions. Implantable and injectable devices promise sustained release, enhancing patient compliance. 3D printing introduces personalized dosage forms, and artificial intelligence empowers data-driven adjustments to treatment plans. Collaboration and interdisciplinary research emerge as crucial drivers, ensuring the translation of innovative concepts into practical applications. From a global health perspective, these innovations address healthcare disparities, promising a future where medications are precisely delivered offering tailored and effective treatment options for diverse populations worldwide.

**Keywords:** Drug delivery systems; Precision medicine; Nanotechnology; RNA therapeutics; Implantable devices; 3D printing; Artificial intelligence

### 1. Introduction

The field of pharmaceuticals has witnessed remarkable advancements in drug delivery systems, paving the way for more effective and patient-centric healthcare. Innovations in drug delivery aim to enhance the therapeutic efficacy of pharmaceutical agents and address the critical issue of patient compliance (Govender, Abrahmsén-Alami, Larsson, & Folestad, 2020; Seyhan & Carini, 2019; Yadav, Kapse-Mistry, Peters, & Mayur, 2019). Amidst these developments, the pharmacist emerges as a pivotal figure in ensuring the successful implementation of these systems, playing a vital role in educating patients on their use and collaborating with healthcare professionals to optimize therapeutic outcomes.

The landscape of drug delivery has evolved significantly over the years, driven by the need for targeted and controlled release of therapeutic agents. Traditional oral and injectable methods, while effective, often face challenges related to variable absorption rates, adverse side effects, and patient adherence (Boffito, Jackson, Owen, & Becker, 2014; Khan & Roberts, 2018; Lewis & Richard, 2015). In response to these challenges, researchers and pharmaceutical companies have been actively exploring novel drug delivery systems that offer precision, reduced side effects, and improved patient

\* Corresponding author: Obe Destiny Balogun

compliance (Adepu & Ramakrishna, 2021; Anselmo & Mitragotri, 2014; Jain, 2020; Sandler & Preis, 2016). These innovations range from advanced oral formulations and injectable technologies to transdermal patches, inhalation devices, and cutting-edge nanotechnology-based carriers (Bajracharya, Song, Back, & Han, 2019; Keservani, Kesharwani, & Sharma, 2023; Kumar, Pandey, & Jain, 2016). The aim is to optimize drug bioavailability and tailor delivery mechanisms to specific patient needs, ensuring a more personalized and practical approach to healthcare.

In this dynamic landscape, the pharmacist's role has transformed from a dispenser of medications to an integral healthcare team member actively involved in patient care (Mohiuddin, 2020; Mossialos et al., 2015; Schindel et al., 2017). Traditionally, pharmacists focused on ensuring the accuracy of prescriptions and providing basic information about medications (Ghaibi, Ipema, & Gabay, 2015; Odukoya & Chui, 2013). However, with the advent of sophisticated drug delivery systems, their responsibilities have expanded to include educating patients about the intricacies of these systems, monitoring therapy outcomes, and collaborating with other healthcare professionals to fine-tune treatment plans. Pharmacists are uniquely positioned to bridge the gap between patients and evolving drug delivery technologies (Hillery, Lloyd, & Swarbrick, 2003; Owusu-Obeng et al., 2014). Their expertise in pharmaceuticals, coupled with their accessibility to patients, positions them as key educators and advocates for medication adherence. As gatekeepers of drug information, pharmacists can demystify complex drug delivery processes, address patient concerns, and empower individuals to actively participate in their therapeutic journey (Mitchell et al., 2012; Snoswell, Cossart, Chevalier, & Barras, 2022).

This research paper seeks to provide a comprehensive review of drug delivery system innovations, explicitly focusing on the pharmacist's role in enhancing efficacy and patient compliance. By exploring the latest advancements in drug delivery technologies and examining the evolving responsibilities of pharmacists, this paper aims to shed light on the symbiotic relationship between these two components of modern healthcare. The overarching goal is to contribute to a deeper understanding of the challenges and opportunities of integrating innovative drug delivery systems into routine patient care. Through this exploration, we endeavour to identify gaps in existing research, offer insights into the impact of pharmacist interventions, and highlight future directions for research and practice in pharmaceutical care.

Innovations in drug delivery systems mark a paradigm shift in pharmaceutical care, and the pharmacist's role is crucial in realizing the full potential of these advancements. By comprehensively reviewing the latest developments in drug delivery and examining the pharmacist's evolving responsibilities, this paper aims to underscore their role in enhancing therapeutic efficacy and promoting patient compliance. Through this exploration, we aim to contribute to the ongoing dialogue on integrating advanced drug delivery technologies into mainstream healthcare practices, ultimately fostering a more patient-centred and practical approach to medication management.

---

## 2. Literature Review

Drug delivery systems have evolved significantly, reflecting the relentless pursuit of more efficient, targeted, and patient-friendly pharmaceutical interventions. Traditional modes of drug administration, such as oral tablets and injectables, have laid the foundation for modern innovations aimed at overcoming limitations associated with variable absorption, side effects, and non-compliance.

### 2.1. Historical Perspective

The historical evolution of drug delivery systems showcases the journey from simple formulations to sophisticated, technology-driven approaches. Early civilizations utilized herbal concoctions and crude extracts for therapeutic purposes (Giannenas, Sidiropoulou, Bonos, Christaki, & Florou-Paneri, 2020; Pan et al., 2014). The advent of pharmaceutical sciences resulted in more controlled drug formulations. The introduction of sustained-release tablets in the mid-20th century represented a landmark shift, allowing for extended drug release and reduced dosing frequency (Lees, Fink-Gremmels, & Toutain, 2013; L. Li, 2021; Sullivan, Sullivan, & Ballantyne, 2023).

In recent decades, nanotechnology, biotechnology, and materials science advancements have spurred the development of highly specialized drug delivery systems. Nanoparticles, liposomes, and micelles have become integral to targeted drug delivery, enabling precise control over drug release kinetics and enhancing therapeutic outcomes. Several key advancements in drug delivery technology include:

#### 2.1.1. Oral Drug Delivery

Oral drug delivery remains the most common and preferred route due to its convenience. Recent innovations in this field are focused on overcoming challenges related to bioavailability, degradation, and variability in absorption rates. Enteric-coated formulations, gastroretentive systems, and nanoparticle-based carriers are among the key

advancements that enhance the efficacy of oral drug delivery. These technologies ensure that medications are absorbed optimally, providing consistent therapeutic outcomes (Alqahtani, Kazi, Alsenaidy, & Ahmad, 2021; Bala, Pawar, Khanna, & Arora, 2013; Kaur, Arora, & Kumar, 2019).

### *2.1.2. Injectable Drug Delivery*

Injectable drug delivery, including subcutaneous, intramuscular, and intravenous routes, plays a vital role in administering critical medications. Advances in controlled-release formulations, biodegradable polymers, and microneedle technologies have significantly improved the precision and safety of injectable drug delivery. These innovations contribute to better patient compliance, reduced side effects, and the ability to tailor drug release profiles for specific therapeutic needs (Maglalang et al., 2018; Rosenberg, 2010; Y. Zhang, Zhang, Ghosh, & Williams III, 2020).

### *2.1.3. Transdermal Drug Delivery*

Transdermal drug delivery systems offer a non-invasive and controlled approach, bypassing the first-pass metabolism associated with oral administration. Patches delivering medications through the skin provide a sustained release, ensuring steady plasma concentrations. Microneedle patches represent a further enhancement in transdermal drug delivery by facilitating the transport of macromolecules. These advancements enhance patient comfort, compliance, and the overall effectiveness of transdermal drug delivery (Akhtar, Singh, Yusuf, & Khan, 2020; Mathias & Hussain, 2010; Upadhyay, Verma, Parvez, & Sharma, 2014).

### *2.1.4. Inhalation Drug Delivery*

Inhalation drug delivery proves particularly effective for respiratory and systemic conditions. Refinements in metered-dose inhalers, dry powder inhalers, and nebulizers have optimized drug delivery to the lungs. Particulate engineering and the development of novel inhalation devices contribute to improved efficacy and reduced side effects. Inhalation drug delivery is critical for treating conditions such as asthma, chronic obstructive pulmonary disease (COPD), and systemic infections (Courrier, Butz, & Vandamme, 2002; Paranjpe & Müller-Goymann, 2014; Tiwari et al., 2012).

### *2.1.5. Novel Approaches*

Revolutionary approaches such as nanoparticles and liposomes have transformed drug delivery. Nanoparticles enable targeted drug delivery to specific cells or tissues, minimizing systemic exposure and enhancing therapeutic efficacy. Liposomes, lipid-based vesicles, improve drug solubility and stability while facilitating controlled release. These novel technologies open new avenues for personalized medicine, enabling the development of tailored treatment modalities that consider individual patient characteristics and needs. The exploration of these advanced approaches holds great promise for the future of drug delivery and healthcare (Battaglia & Gallarate, 2012; Bhatia & Bhatia, 2016; Chaturvedi, Singh, Singh, & Singh, 2019; Khanbabaie & Jahanshahi, 2012; Schindel et al., 2017).

## **2.2. The Pharmacist's Role in Drug Delivery**

Historically positioned as medication dispensers, pharmacists now play an instrumental role in optimizing drug therapy through their involvement in drug delivery. The pharmacist's expanding responsibilities encompass patient education, collaboration with healthcare professionals, and ensuring adherence to complex drug regimens.

Traditionally, pharmacists focused on accurately dispensing medications and providing patients with basic information. However, as drug delivery systems became more intricate, pharmacists adapted their roles to encompass a broader scope of patient care. The concept of pharmaceutical care emerged, emphasizing the pharmacist's responsibility for ensuring optimal medication use and patient outcomes. The pharmacist's role has evolved into a multifaceted one, integrating aspects of medication therapy management, patient counseling, and collaboration with healthcare teams. This transformation aligns with the broader shift in healthcare towards a patient-centred model, where pharmacists are recognized as essential contributors to patients' overall well-being (Goode, Owen, Page, & Gatewood, 2019; Schindel et al., 2017).

Pharmacist involvement in drug delivery extends beyond the pharmacy counter (Blouin & Adams, 2017; Merks et al., 2021). Patients must comprehend the intricacies of their prescribed drug delivery systems to ensure proper usage. Pharmacists serve as educators, offering clear explanations of drug delivery mechanisms, administration techniques, and potential side effects. This educational role is pivotal in fostering patient empowerment and informed decision-making—the collaborative nature of modern healthcare demands effective communication and cooperation among healthcare professionals. Pharmacists actively engage with physicians, nurses, and other healthcare team members to optimize drug therapy (Jorgenson, Dalton, Farrell, Tsuyuki, & Dolovich, 2013; Lee, Alshehri, Kutbi, & Martin, 2015). This

collaborative approach ensures drug delivery systems align with patient needs, medical conditions, and overall treatment goals.

Patient adherence to prescribed medication regimens is a longstanding challenge in healthcare. Complex drug delivery systems can exacerbate this issue due to increased potential for misunderstanding and misuse (Devadasu, Bhardwaj, & Kumar, 2013; Tan, Feldman, Chang, & Balkrishnan, 2012). Pharmacists address this challenge through comprehensive patient counseling, emphasizing the importance of adherence, potential side effects, and the role of the drug in managing the underlying condition. Pharmacists leverage their accessibility and expertise to bridge the gap between healthcare providers and patients (Osae, Chastain, & Young, 2022; Peckham et al., 2021). They tailor their counseling to individual patient needs, considering health literacy, cultural background, and lifestyle factors. Pharmacists contribute significantly to enhancing patient compliance and overall treatment efficacy through this personalized approach (Milosavljevic, Aspden, & Harrison, 2018; Morgado, Morgado, Mendes, Pereira, & Castelo-Branco, 2011; Van Wijk, Klungel, Heerdink, & de Boer, 2005).

Despite the progress in drug delivery systems and the expanding role of pharmacists, challenges persist. Patient education requires time and resources, particularly in intricate drug delivery systems (Adebukola, Navya, Jordan, Jenifer, & Begley, 2022; Tiwari et al., 2012). Pharmacists may face barriers related to time constraints, workload, and the need for continuous professional development to stay abreast of evolving technologies (Bou-Saba, Kassak, & Salameh, 2022). Interdisciplinary collaboration poses another challenge, as effective communication among healthcare professionals is essential for seamless patient care. Overcoming these challenges requires a concerted effort from healthcare organizations, policymakers, and educational institutions to prioritize and support the evolving role of pharmacists in the context of advanced drug delivery systems.

While considerable research has focused on drug delivery systems and the pharmacist's role, specific gaps persist in the literature. The integration of advanced drug delivery technologies into routine clinical practice is an area that requires further exploration. Studies assessing the impact of pharmacist interventions on patient outcomes in the context of specific drug delivery systems are limited. Additionally, there is a need for research addressing the challenges pharmacists face in adopting and implementing new drug delivery technologies. Understanding the barriers to effective patient education, interdisciplinary collaboration, and the integration of technological advancements is crucial for developing strategies to enhance the pharmacist's role in the era of advanced drug delivery.

In summary, the literature on drug delivery systems and the pharmacist's role reflects a dynamic landscape marked by continuous innovation and evolving healthcare paradigms. As drug delivery technologies become more sophisticated, the pharmacist's responsibilities expand to ensure the successful integration of these innovations into patient care. Addressing gaps in research and overcoming existing challenges will further strengthen the pharmacist's position as a key player in enhancing the efficacy and patient compliance of advanced drug delivery systems.

---

### 3. Drug Delivery Systems: Advancements and Innovations

Drug delivery systems have undergone significant advancements in recent years in the relentless pursuit of optimizing therapeutic outcomes and enhancing patient compliance. These innovations aim to address challenges associated with traditional drug administration methods, such as oral tablets and injectables, by providing more precise, targeted, and patient-friendly approaches. This comprehensive review explores critical drug delivery systems, including oral, injectable, transdermal, inhalation, and novel approaches like nanoparticles and liposomes. It highlights their mechanisms, advantages, and potential impact on healthcare.

#### 3.1. Oral Drug Delivery Systems

Oral drug delivery remains the most common and preferred route due to its convenience, patient acceptance, and non-invasiveness. Recent innovations in oral drug delivery systems focus on overcoming challenges related to variable absorption rates, degradation in the gastrointestinal tract, and the need for frequent dosing.

- *Enteric-Coated Formulations:* These resist dissolution in the stomach, ensuring drug release in the intestines. This approach is crucial for drugs sensitive to gastric acidity or enzymes. By protecting the drug from premature degradation, enteric coatings improve bioavailability and therapeutic efficacy (Katona et al., 2022).
- *Gastroretentive Systems:* They aim to prolong gastric residence time, ensuring sustained drug release. Floating and mucoadhesive systems are common strategies. These systems enhance drug absorption, especially for drugs with absorption windows in specific gastrointestinal tract segments (Streubel, Siepmann, & Bodmeier, 2006).

- *Nanoparticle-Based Carriers*: Nanoparticle-based oral drug delivery involves encapsulating drugs in nanoscale carriers, such as liposomes or polymeric nanoparticles. This approach improves drug solubility, stability, and bioavailability. Nanoparticles protect drugs from enzymatic degradation and facilitate targeted delivery to specific tissues (Yu et al., 2016).

### 3.2. Injectable Drug Delivery Systems

Injectable drug delivery systems are crucial for administering critical medications, offering rapid and precise delivery. Advancements in this area focus on controlled-release formulations, biodegradable polymers, and novel injection devices to enhance safety and patient compliance.

- *Controlled-Release Formulations*: Controlled-release formulations aim to extend drug release over an extended period, reducing the frequency of injections. This is particularly relevant for chronic conditions. These formulations employ various mechanisms, such as diffusion-controlled, osmotically controlled, and matrix-controlled release, to achieve sustained therapeutic concentrations (N. Li et al., 2021).
- *Biodegradable Polymers*: These play a vital role in injectable drug delivery. These polymers break down into non-toxic byproducts, eliminating the need for removal or extraction after drug release. Biodegradable microspheres and implants provide sustained drug release while minimizing the risk of adverse effects (Z. Zhang, Ortiz, Goyal, & Kohn, 2014).
- *Microneedle Technologies*: They have emerged as minimally invasive alternatives for drug delivery. Microneedles, typically ranging from hundreds of micrometres to a few millimetres in length, painlessly penetrate the skin to deliver drugs. This approach is particularly relevant for vaccines, insulin, and other therapeutics (Ingrole et al., 2021; Richter-Johnson, Kumar, Choonara, du Toit, & Pillay, 2018).

### 3.3. Transdermal Drug Delivery Systems

Transdermal drug delivery systems offer a non-invasive and controlled approach, avoiding first-pass metabolism associated with oral administration. These systems provide a steady release of drugs through the skin, ensuring prolonged therapeutic effects.

- *Transdermal Patches*: They are adhesive systems containing drugs released slowly and steadily through the skin. These patches are convenient, offering prolonged drug delivery with reduced side effects. They are commonly used for pain management, hormone replacement therapy, and smoking cessation (Dhiman, Singh, & Rehni, 2011).
- *Microneedle Patches*: They combine the benefits of transdermal delivery with the precision of microneedle technology. These patches have tiny needles that painlessly penetrate the skin to deliver drugs, including macromolecules that would not be effectively absorbed through traditional transdermal patches (Peng et al., 2021; Perez Cuevas et al., 2018).

### 3.4. Inhalation Drug Delivery Systems

Inhalation drug delivery is particularly effective for respiratory and systemic conditions, offering rapid absorption and targeted delivery to the lungs. Advances in inhalation drug delivery focus on improving the efficiency of delivery devices and enhancing the formulations for various respiratory medications.

- *Metered-Dose Inhalers (MDIs)*: MDIs deliver a precise dose of medication in aerosol form, allowing patients to inhale the medication into their lungs. Propellant-based MDIs have been widely used for bronchodilators and anti-inflammatory medications. Improvements in propellant-free technologies aim to reduce environmental impact (Newman, 2005).
- *Dry Powder Inhalers (DPIs)*: DPIs deliver medications in a powdered form, activated by the patient's inhalation. These devices are preferred for their ease of use and lack of propellants. DPIs are suitable for a range of medications, including corticosteroids and bronchodilators (Chougule, Padhi, Jinturkar, & Misra, 2007).
- *Nebulizers*: Nebulizers transform liquid medications into a fine mist, which patients inhale through a mask or mouthpiece. These devices are often used for patients with severe respiratory conditions who may have difficulty using MDIs or DPIs. Advances in nebulizer technology aim to enhance drug delivery efficiency (Cazzola, Ora, Bianco, Rogliani, & Matera, 2021; Terry & Dhand, 2023).

### 3.5. Novel Approaches

Novel drug delivery approaches leverage nanotechnology and liposomal carriers to enhance drug solubility, stability, and targeted delivery. These systems can revolutionize personalized medicine by enabling precise drug delivery to specific cells or tissues.

- *Nanoparticles*: Nanoparticles, typically in the range of 1 to 100 nanometers (Scott, Ewim, & Eloka-Eboka, 2022), can encapsulate drugs, protecting them from degradation and improving bioavailability (Mendoza-Munoz, Urbán-Morlán, Leyva-Gómez, de la Luz Zambrano-Zaragoza, & Quintanar-Guerrero, 2021). These carriers can passively target diseased tissues through the enhanced permeability and retention (EPR) effect or be actively targeted using ligands.
- *Liposomes*: Liposomes are lipid-based vesicles that encapsulate hydrophobic and hydrophilic drugs. Liposomal formulations enhance drug stability, improve solubility, and allow controlled release. Liposomes can also be modified for targeted drug delivery by attaching specific ligands (Grimaldi et al., 2016).

In conclusion, the landscape of drug delivery systems has witnessed transformative advancements across various modalities, from traditional oral formulations to cutting-edge nanotechnology-based carriers. These innovations seek to overcome challenges associated with traditional drug administration and offer opportunities for more targeted and personalized therapeutic interventions. The pharmacist's role becomes increasingly vital in this dynamic landscape as they take on responsibilities beyond mere dispensing, engaging in patient education, collaborating with healthcare professionals, and ensuring adherence to complex drug regimens. As the pharmaceutical industry continues exploring novel drug delivery approaches, healthcare professionals and researchers must stay abreast of these developments. The ongoing integration of advanced drug delivery technologies into routine clinical practice has the potential to reshape the landscape of healthcare, providing patients with more effective and tailored treatment options. Moreover, addressing challenges and identifying opportunities in drug delivery research will further propel the field toward a future where the promise of precision medicine is realized through innovative and patient-centric drug delivery systems.

---

## 4. The Evolving Role of Pharmacists in Drug Delivery

The healthcare landscape continuously transforms, and pharmacists are at the forefront of this evolution. Traditionally perceived as medication dispensers, pharmacists have seen their roles expand dramatically. One of the areas where this evolution is most pronounced is in drug delivery systems. This paper explores pharmacists' multifaceted and increasingly critical role in drug delivery, focusing on how they enhance therapeutic efficacy and ensure patient compliance.

Historically, pharmacists have been synonymous with ensuring the accuracy of prescriptions and providing basic information about medications. Their primary responsibilities included dispensing medications, managing inventory, and offering rudimentary guidance to patients. However, as healthcare paradigms shifted towards patient-centred models, the role of pharmacists expanded beyond these traditional functions. The concept of pharmaceutical care, introduced by Hepler and Strand in the 1990s, marked a turning point in the profession (Hepler, 2004; van Mil, Schulz, & Tromp, 2004; Zellmer, 2001). Pharmaceutical care emphasizes the pharmacist's responsibility for ensuring optimal medication use, monitoring therapy outcomes, and actively engaging with patients to address their healthcare needs. This paradigm shift recognizes pharmacists as integral members of the healthcare team rather than mere suppliers of medications.

Pharmacists play a pivotal role in patient education in drug delivery systems (Hillery et al., 2003). With increasingly complex drug delivery technologies, the pharmacist's responsibility is to dispense medications and ensure that patients understand the intricacies of their prescribed regimens. This includes explaining the mechanism of action, proper administration techniques, potential side effects, and the importance of adherence. Effective communication is paramount, as patients need to comprehend the rationale behind specific drug delivery systems. Whether understanding the delayed release of medication in enteric-coated formulations or the steady absorption achieved through transdermal patches, patients rely on pharmacists to demystify these processes, fostering a sense of empowerment and informed decision-making.

Pharmacists are increasingly recognized for their collaborative contributions to patient care. In drug delivery, this collaboration extends to working closely with physicians, nurses, and other healthcare professionals to optimize treatment plans. Understanding the patient's medical history, comorbidities, and lifestyle factors enables pharmacists to provide valuable insights into selecting appropriate drug delivery systems. Interdisciplinary collaboration is

particularly crucial in injectable drug delivery systems, where pharmacists may liaise with healthcare teams to determine the most suitable formulations and administration schedules (Bates et al., 1999; Rosenfeld et al., 2018). This collaborative approach ensures that drug delivery aligns with the broader healthcare strategy and contributes to improved patient outcomes.

Enhancing patient adherence to prescribed medication regimens is a longstanding challenge in healthcare. The complexity of drug delivery systems can further exacerbate this issue. Pharmacists address this challenge through comprehensive patient counseling. They emphasize the importance of adherence, the potential consequences of missed doses, and strategies to mitigate side effects. Effective counseling is tailored to individual patient needs, considering health literacy, cultural background, and lifestyle factors. Pharmacists provide information and engage in dialogue, encouraging patients to express concerns and ask questions. This patient-centered approach fosters a collaborative relationship, making patients more likely to adhere to their prescribed drug delivery regimens.

Beyond the point of dispensing medications, pharmacists actively monitor and assess therapy outcomes. This involves ongoing evaluation of the effectiveness of drug delivery systems in achieving therapeutic goals. Pharmacists may collaborate with patients to gather feedback on their experiences with specific drug delivery methods, identifying potential issues or areas for improvement. In inhalation drug delivery, for instance, pharmacists may assess the patient's inhalation technique, ensuring proper use of devices like metered-dose inhalers or dry powder inhalers. Regular follow-ups allow pharmacists to address any challenges or concerns, optimizing the effectiveness of the prescribed drug delivery system (Eldooma, Maatoug, & Yousif, 2023; Ensing et al., 2015).

The evolving role of pharmacists in drug delivery also includes addressing challenges and concerns related to these advanced technologies. Patients may express apprehensions about using specific drug delivery systems, such as injections or inhalers. Pharmacists are equipped to alleviate these concerns through education, demonstration, and empathetic communication. Moreover, pharmacists may encounter challenges in implementing and adapting new drug delivery technologies. Continuous professional development is essential to staying abreast of innovations and refining their skill set to navigate the complexities of modern drug delivery (Jain, 2008). Addressing these challenges ensures that pharmacists remain effective advocates for patients in the rapidly evolving landscape of pharmaceutical care.

Pharmacists are instrumental in ensuring regulatory compliance related to drug delivery systems (Paulino, Thomas, Lee, & Cooper, 2019). They stay informed about the latest guidelines, safety protocols, and quality assurance measures associated with various drug delivery technologies. This commitment to regulatory compliance safeguards patient well-being and contributes to the healthcare system's overall integrity. Pharmacists engage in ongoing education and training to adhere to evolving regulatory standards (Albanese, Rouse, Schlaifer, & Pharmacy, 2010). This includes understanding the requirements for storing, handling, and dispensing medications delivered through innovative systems such as biodegradable implants or gene therapies.

The evolving role of pharmacists in drug delivery systems encapsulates a profound shift from a transactional model to one centered around patient care, education, and collaboration. As drug delivery technologies become increasingly sophisticated, pharmacists emerge as key players in ensuring that patients receive their medications, understand the nuances of how these medications are delivered, and contribute to overall health. Pharmacists' contributions extend beyond the pharmacy counter, encompassing patient education, interdisciplinary collaboration, and continuous efforts to enhance adherence. In this dynamic landscape, pharmacists are essential advocates for patients, empowering them to actively participate in their therapeutic journey and fostering a holistic approach to pharmaceutical care. As drug delivery systems continue to advance, the role of pharmacists will undoubtedly evolve further, shaping the future of healthcare through their commitment to patient-centric and effective medication management.

---

## **5. Impact of Drug Delivery Systems on Therapeutic Efficacy and Patient Compliance**

Developing and integrating advanced drug delivery systems in healthcare have profound implications for therapeutic efficacy and patient compliance. The effectiveness of a treatment regimen is intricately linked to how medications are delivered to the body. This paper delves into the impact of drug delivery systems on therapeutic efficacy and patient compliance, exploring how innovations in this domain contribute to enhanced treatment outcomes and improved adherence.

### **5.1. Enhancing Therapeutic Efficacy**

Drug delivery systems play a crucial role in optimizing therapeutic efficacy by addressing specific challenges associated with traditional methods of drug administration. Several factors contribute to the enhanced efficacy observed with advanced drug delivery systems.

Innovative drug delivery technologies, such as nanoparticles and liposomes, enable precise targeting of therapeutic agents to specific cells or tissues. This precision minimizes off-target effects and enhances the concentration of the drug at the intended site of action. Consequently, therapeutic efficacy is improved, reducing the potential for adverse reactions. Controlled-release formulations, including sustained-release tablets and transdermal patches, facilitate a gradual and prolonged release of medications. This controlled release ensures a steady therapeutic effect and reduces dosing frequency. Patients benefit from sustained drug concentrations, leading to more consistent outcomes and improved treatment effectiveness.

Drug delivery systems address challenges related to drug solubility and bioavailability (Adebukola et al., 2022; Boyd et al., 2019; Maduka et al., 2023; Okunade, Adediran, Maduka, & Adegoke, 2023; Wen, Jung, & Li, 2015). Formulations that enhance solubility and protect drugs from degradation in the gastrointestinal tract contribute to increased absorption. This optimization of bioavailability ensures that a higher proportion of the administered dose reaches the systemic circulation, maximizing the therapeutic impact of the medication. Advances in drug delivery pave the way for personalized medicine approaches. Tailoring drug formulations to individual patient characteristics, such as genetics or metabolism, allows for a more customized treatment strategy. Personalized drug delivery systems can account for variability in patient responses, ultimately leading to better therapeutic outcomes.

### **5.2. Improving Patient Compliance**

Patient compliance, defined as the extent to which patients adhere to prescribed medication regimens, is a critical determinant of treatment success. Drug delivery systems contribute significantly to improving patient compliance through various mechanisms.

Many advanced drug delivery systems, such as long-acting injectables or once-daily formulations, reduce the frequency of dosing. This simplification of the dosing regimen is critical to enhancing patient compliance. Patients are more likely to adhere to treatments that require less frequent administration, leading to better long-term outcomes. Controlled-release formulations and targeted drug delivery minimize fluctuations in drug concentrations, reducing the incidence of side effects. Patients may be more willing to adhere to treatments that offer a favorable side effect profile. Mitigating adverse reactions contributes to a positive patient experience, fostering continued adherence to the prescribed regimen (Jantzen & Robinson, 2002; Ummadi, Shravani, Rao, Reddy, & Sanjeev, 2013).

Innovations in drug delivery also address issues of tolerability. For example, transdermal patches or inhalation devices provide alternative routes of administration that are better tolerated by specific patient populations (Mathias & Hussain, 2010). Improved tolerability enhances the overall acceptability of the treatment, encouraging patients to adhere to their medication schedules. Drug delivery systems often necessitate patient education regarding their proper use and potential benefits. As critical healthcare educators, pharmacists are central to enhancing patient understanding. Clear explanations about the advantages of specific drug delivery methods, combined with practical demonstrations, empower patients and contribute to better adherence (Costa et al., 2015).

### **5.3. Challenges and Considerations**

While the impact of drug delivery systems on efficacy and compliance is substantial, challenges persist. Patients may face barriers related to the complexity of specific drug delivery methods, and healthcare professionals must navigate these challenges to maximize the benefits of innovative technologies.

Patients' health literacy levels vary and challenge effective communication about drug delivery systems. Ensuring patients understand the nuances of their prescribed regimen requires targeted educational strategies. Pharmacists, in particular, play a critical role in simplifying complex information and addressing patient concerns. The success of drug delivery systems relies on seamless interdisciplinary collaboration. Effective communication among healthcare professionals is essential to align treatment plans with patient needs. Pharmacists must collaborate with physicians and other healthcare providers to ensure that the chosen drug delivery system aligns with the treatment strategy. Some advanced drug delivery systems may be associated with higher costs, potentially impacting patient access and adherence. The financial burden of specific formulations may lead to non-adherence or discontinuation. Pharmacists can address these challenges by exploring cost-effective alternatives and advocating for patient assistance programs.



In conclusion, the impact of drug delivery systems on therapeutic efficacy and patient compliance is multifaceted and transformative. Innovations in drug delivery enhance the precision and effectiveness of treatments and contribute to patient-centered care by addressing issues related to adherence and tolerability. The ability of drug delivery systems to provide targeted, controlled, and personalized therapeutic interventions represents a paradigm shift in healthcare. From nanoparticles enabling precision targeting to transdermal patches simplifying dosing regimens, these advancements align with the broader goal of improving patient outcomes and quality of life.

As key stakeholders in patient care, pharmacists are uniquely positioned to navigate the complexities of drug delivery systems. Their roles extend beyond dispensing medications to actively educating patients, promoting adherence, and collaborating with healthcare teams to optimize treatment strategies. By addressing challenges and fostering patient understanding, pharmacists contribute significantly to successfully integrating innovative drug delivery technologies into routine clinical practice. The continued evolution of drug delivery systems holds promise for the future of healthcare, where treatments are efficacious but also patient-centric and accessible. As research and development in this field progress, pharmacists will remain pivotal in translating these innovations into tangible patient benefits, ultimately shaping a healthcare landscape prioritizing therapeutic efficacy and patient well-being.

---

## **6. Future Trends and Opportunities in Drug Delivery Systems**

As we stand at the intersection of pharmaceutical innovation and healthcare transformation, the future of drug delivery systems promises groundbreaking advancements that will redefine the landscape of patient care. Several emerging trends and opportunities are shaping the trajectory of this field, offering a glimpse into a future where precision medicine and personalized therapies take center stage.

### **6.1. Nanotechnology and Targeted Drug Delivery**

Nanotechnology is poised to revolutionize drug delivery by enabling targeted and personalized treatment strategies. Nanoparticles, with their unique properties and dimensions at the nanoscale, can be engineered to carry therapeutic agents directly to specific cells or tissues. This precision targeting minimizes systemic exposure, reduces side effects, and enhances the therapeutic efficacy of medications. Future drug delivery systems are likely to harness the potential of nanotechnology for tailored treatment approaches, offering a new era of precision medicine (Sakamoto et al., 2010).

### **6.2. RNA Therapeutics and Gene Delivery**

The advent of RNA therapeutics, including mRNA and siRNA, has opened up unprecedented possibilities for treating genetic disorders and various diseases at the molecular level (Kim, 2022). However, delivering these fragile molecules intact to their target sites poses a significant challenge. Future drug delivery systems will explore innovative approaches, such as lipid nanoparticles and viral vectors, to facilitate the safe and effective delivery of RNA therapeutics. This opens the door to groundbreaking treatments that can address the root causes of diseases at the genetic level.

### **6.3. Implantable and Injectable Devices**

The future of drug delivery systems includes a shift towards implantable and injectable devices designed for long-term, sustained release of medications. Biodegradable implants and injectables offer the advantage of extended therapeutic effects while minimizing the need for frequent dosing (Dash & Cudworth II, 1998). This trend not only improves patient compliance but also opens avenues for the treatment of chronic conditions. Implantable devices may also incorporate sensors to monitor therapeutic responses and adjust drug release in real-time, ushering in an era of adaptive and personalized drug delivery.

### **6.4. 3D Printing and Personalized Dosage Forms**

3D printing technology is poised to transform the manufacturing of pharmaceuticals, allowing for the creation of personalized dosage forms tailored to individual patient needs (Aquino, Barile, Grasso, & Saviano, 2018; Pravin & Sudhir, 2018). This trend presents an opportunity to customize drug delivery based on factors such as patient demographics, genetics, and specific health conditions. Personalized dosage forms can optimize drug absorption, reduce adverse effects, and enhance overall treatment outcomes, marking a significant step towards patient-centric healthcare.

### **6.5. AI and Smart Drug Delivery**

The integration of artificial intelligence into drug delivery systems holds immense potential for optimizing treatment regimens (Hassanzadeh, Atyabi, & Dinarvand, 2019). AI algorithms can analyze patient data, predict therapeutic responses, and recommend personalized drug delivery strategies. Smart drug delivery devices equipped with sensors

and connectivity can provide real-time data on patient adherence and physiological responses. This feedback loop enables healthcare providers to make data-driven adjustments to treatment plans, fostering a proactive and responsive approach to patient care.

### 6.6. Collaboration and Interdisciplinary Research

Future trends in drug delivery systems emphasize the importance of collaboration and interdisciplinary research. The convergence of nanotechnology, materials science, pharmacology, and engineering expertise is essential for developing holistic solutions (M. Roco, Bainbridge, Tonn, & Whitesides, 2013; M. C. Roco, 2003). Collaborative efforts between researchers, clinicians, and industry stakeholders will accelerate the translation of innovative concepts into practical applications, ensuring that the full potential of drug delivery innovations is realized.

### 6.7. Global Health and Access to Medications

The future of drug delivery systems must address global health challenges, focusing on improving access to essential medications. Innovations that enhance the stability and transportability of drugs, especially in resource-limited settings, will play a crucial role. Affordable and scalable drug delivery solutions can bridge the healthcare disparities gap, ensuring that the benefits of advanced therapies reach diverse populations worldwide (Dubé et al., 2014; Signé, 2021).

---

## 7. Conclusion

In conclusion, the future of drug delivery systems is marked by a convergence of groundbreaking innovations that promise to redefine the healthcare landscape. As we embark on the journey towards precision medicine, integrating nanotechnology, RNA therapeutics, implantable devices, 3D printing, artificial intelligence, and collaborative interdisciplinary research signals a paradigm shift in patient care. The potential of nanotechnology for targeted drug delivery opens avenues for precise treatment strategies, minimizing side effects, and maximizing therapeutic efficacy. RNA therapeutics and gene delivery herald a new era of molecular-level interventions, addressing diseases at their genetic roots. Implantable and injectable devices, designed for sustained release, offer a pathway to improved patient compliance and the treatment of chronic conditions.

3D printing technology introduces the concept of personalized dosage forms, tailoring drug delivery to individual patient needs. Artificial intelligence, coupled with smart drug delivery devices, empowers healthcare providers with real-time data for data-driven adjustments to treatment plans, ushering in a proactive approach to patient care. Crucially, collaboration and interdisciplinary research emerge as linchpins in this transformative journey. The convergence of expertise from diverse fields is essential for translating innovative concepts into practical applications that benefit patients globally. As these advancements unfold, the emphasis on global health and improved access to medications ensures that the benefits of advanced therapies reach diverse populations, addressing healthcare disparities.

The future of drug delivery systems holds the promise of patient-centric, adaptive, and responsive healthcare. By embracing these trends, the healthcare industry stands at the precipice of a new era where medications are administered and precisely delivered to achieve optimal therapeutic outcomes. Through these innovations, the vision of a healthcare landscape that is both technologically advanced and universally accessible becomes increasingly tangible, offering hope for a healthier and more equitable future.

---

## Compliance with ethical standards

### *Disclosure of conflict of interest*

No conflict of interest to be disclosed.

---

## References

- [1] Adebukola, A. A., Navya, A. N., Jordan, F. J., Jenifer, N. J., & Begley, R. D. (2022). Cyber Security as a Threat to Health Care. *Journal of Technology and Systems*, 4(1), 32-64.
- [2] Adepu, S., & Ramakrishna, S. (2021). Controlled drug delivery systems: current status and future directions. *Molecules*, 26(19), 5905.

- [3] Akhtar, N., Singh, V., Yusuf, M., & Khan, R. A. (2020). Non-invasive drug delivery technology: Development and current status of transdermal drug delivery devices, techniques and biomedical applications. *Biomedical Engineering/Biomedizinische Technik*, 65(3), 243-272.
- [4] Albanese, N. P., Rouse, M. J., Schlaifer, M., & Pharmacy, C. o. C. i. (2010). Scope of contemporary pharmacy practice: roles, responsibilities, and functions of pharmacists and pharmacy technicians. *Journal of the American Pharmacists Association*, 50(2), e35-e69.
- [5] Alqahtani, M. S., Kazi, M., Alsenaidy, M. A., & Ahmad, M. Z. (2021). Advances in oral drug delivery. *Frontiers in pharmacology*, 12, 618411.
- [6] Anselmo, A. C., & Mitragotri, S. (2014). An overview of clinical and commercial impact of drug delivery systems. *Journal of Controlled Release*, 190, 15-28.
- [7] Aquino, R. P., Barile, S., Grasso, A., & Saviano, M. (2018). Envisioning smart and sustainable healthcare: 3D Printing technologies for personalized medication. *Futures*, 103, 35-50.
- [8] Bajracharya, R., Song, J. G., Back, S. Y., & Han, H.-K. (2019). Recent advancements in non-invasive formulations for protein drug delivery. *Computational and structural biotechnology journal*, 17, 1290-1308.
- [9] Bala, R., Pawar, P., Khanna, S., & Arora, S. (2013). Orally dissolving strips: A new approach to oral drug delivery system. *International journal of pharmaceutical investigation*, 3(2), 67.
- [10] Bates, D., Dugger, B., Gosbee, J., Schneider, P., Cousins, D., & Flynn, E. (1999). *Consensus Development Conference on the Safety of Intravenous Drug Delivery Systems Consensus Statement*. Paper presented at the Consensus Development Conference on the Safety of Intravenous Drug Delivery Systems Consensus Statement.
- [11] Battaglia, L., & Gallarate, M. (2012). Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery. *Expert opinion on drug delivery*, 9(5), 497-508.
- [12] Bhatia, S., & Bhatia, S. (2016). Nanoparticles types, classification, characterization, fabrication methods and drug delivery applications. *Natural Polymer Drug Delivery Systems: Nanoparticles, Plants, and Algae*, 33-93.
- [13] Blouin, R. A., & Adams, M. L. (2017). The role of the pharmacist in health care: expanding and evolving. *North Carolina Medical Journal*, 78(3), 165-167.
- [14] Boffito, M., Jackson, A., Owen, A., & Becker, S. (2014). New approaches to antiretroviral drug delivery: challenges and opportunities associated with the use of long-acting injectable agents. *Drugs*, 74, 7-13.
- [15] Bou-Saba, A. W., Kassak, K. M., & Salameh, P. R. (2022). The current trends and challenges towards good community pharmacy practice and the way forward. *Exploratory Research in Clinical and Social Pharmacy*, 6, 100152.
- [16] Boyd, B. J., Bergström, C. A., Vinarov, Z., Kuentz, M., Brouwers, J., Augustijns, P., . . . Pr at, V. (2019). Successful oral delivery of poorly water-soluble drugs both depends on the intraluminal behavior of drugs and of appropriate advanced drug delivery systems. *European Journal of Pharmaceutical Sciences*, 137, 104967.
- [17] Cazzola, M., Ora, J., Bianco, A., Rogliani, P., & Matera, M. G. (2021). Guidance on nebulization during the current COVID-19 pandemic. *Respiratory Medicine*, 176, 106236.
- [18] Chaturvedi, V. K., Singh, A., Singh, V. K., & Singh, M. P. (2019). Cancer nanotechnology: a new revolution for cancer diagnosis and therapy. *Current drug metabolism*, 20(6), 416-429.
- [19] Chougule, M. B., Padhi, B. K., Jinturkar, K. A., & Misra, A. (2007). Development of dry powder inhalers. *Recent Patents on drug delivery & formulation*, 1(1), 11-21.
- [20] Costa, E., Giardini, A., Savin, M., Menditto, E., Lehane, E., Laosa, O., . . . Marengoni, A. (2015). Interventional tools to improve medication adherence: review of literature. *Patient preference and adherence*, 1303-1314.
- [21] Courier, H., Butz, N., & Vandamme, T. F. (2002). Pulmonary drug delivery systems: recent developments and prospects. *Critical Reviews™ in Therapeutic Drug Carrier Systems*, 19(4-5).
- [22] Dash, A., & Cudworth II, G. (1998). Therapeutic applications of implantable drug delivery systems. *Journal of pharmacological and toxicological methods*, 40(1), 1-12.
- [23] Devadasu, V. R., Bhardwaj, V., & Kumar, M. R. (2013). Can controversial nanotechnology promise drug delivery? *Chemical reviews*, 113(3), 1686-1735.

- [24] Dhiman, S., Singh, T. G., & Rehni, A. K. (2011). Transdermal patches: a recent approach to new drug delivery system. *Int J Pharm Pharm Sci*, 3(5), 26-34.
- [25] Dubé, L., Jha, S., Faber, A., Struben, J., London, T., Mohapatra, A., . . . McDermott, J. (2014). Convergent innovation for sustainable economic growth and affordable universal health care: innovating the way we innovate. *Annals of the New York Academy of Sciences*, 1331(1), 119-141.
- [26] Eldooma, I., Maatoug, M., & Yousif, M. (2023). Outcomes of Pharmacist-Led Pharmaceutical Care Interventions Within Community Pharmacies: Narrative Review. *Integrated Pharmacy Research and Practice*, 113-126.
- [27] Ensing, H. T., Stuijt, C. C., Van Den Bemt, B. J., Van Dooren, A. A., Karapinar-Carkit, F., Koster, E. S., & Bouvy, M. L. (2015). Identifying the optimal role for pharmacists in care transitions: a systematic review. *Journal of managed care & specialty pharmacy*, 21(8), 614-636.
- [28] Ghaibi, S., Ipema, H., & Gabay, M. (2015). ASHP guidelines on the pharmacist's role in providing drug information. *American Journal of Health-System Pharmacy*, 72(7), 573-577.
- [29] Giannenas, I., Sidiropoulou, E., Bonos, E., Christaki, E., & Florou-Paneri, P. (2020). The history of herbs, medicinal and aromatic plants, and their extracts: Past, current situation and future perspectives. In *Feed additives* (pp. 1-18): Elsevier.
- [30] Goode, J.-V., Owen, J., Page, A., & Gatewood, S. (2019). Community-based pharmacy practice innovation and the role of the community-based pharmacist practitioner in the United States. *Pharmacy*, 7(3), 106.
- [31] Govender, R., Abrahmsén-Alami, S., Larsson, A., & Folestad, S. (2020). Therapy for the individual: Towards patient integration into the manufacturing and provision of pharmaceuticals. *European Journal of Pharmaceutics and Biopharmaceutics*, 149, 58-76.
- [32] Grimaldi, N., Andrade, F., Segovia, N., Ferrer-Tasies, L., Sala, S., Veciana, J., & Ventosa, N. (2016). Lipid-based nanovesicles for nanomedicine. *Chemical society reviews*, 45(23), 6520-6545.
- [33] Hassanzadeh, P., Atyabi, F., & Dinarvand, R. (2019). The significance of artificial intelligence in drug delivery system design. *Advanced drug delivery reviews*, 151, 169-190.
- [34] Hepler, C. D. (2004). Clinical pharmacy, pharmaceutical care, and the quality of drug therapy. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, 24(11), 1491-1498.
- [35] Hillery, A. M., Lloyd, A. W., & Swarbrick, J. (2003). *Drug delivery and targeting: for pharmacists and pharmaceutical scientists*: Crc press.
- [36] Ingrole, R. S., Azizoglu, E., Dul, M., Birchall, J. C., Gill, H. S., & Prausnitz, M. R. (2021). Trends of microneedle technology in the scientific literature, patents, clinical trials and internet activity. *Biomaterials*, 267, 120491.
- [37] Jain, K. K. (2008). Drug delivery systems-an overview. *drug delivery systems*, 1-50.
- [38] Jain, K. K. (2020). An overview of drug delivery systems. *drug delivery systems*, 1-54.
- [39] Jantzen, G. M., & Robinson, J. R. (2002). Sustained and controlled-release drug delivery systems. *Modern pharmaceutics*, 4, 501-502.
- [40] Jorgenson, D., Dalton, D., Farrell, B., Tsuyuki, R. T., & Dolovich, L. (2013). Guidelines for pharmacists integrating into primary care teams. *Canadian Pharmacists Journal/Revue des Pharmaciens du Canada*, 146(6), 342-352.
- [41] Katona, M. T., Kakuk, M., Szabó, R., Tonka-Nagy, P., Takács-Novák, K., & Borbás, E. (2022). Towards a better understanding of the post-gastric behavior of enteric-coated formulations. *Pharmaceutical Research*, 39(1), 201-211.
- [42] Kaur, G., Arora, M., & Kumar, M. R. (2019). Oral drug delivery technologies—a decade of developments. *Journal of Pharmacology and Experimental Therapeutics*, 370(3), 529-543.
- [43] Keservani, R. K., Kesharwani, R. K., & Sharma, A. K. (2023). *Advances in Novel Formulations for Drug Delivery*: John Wiley & Sons.
- [44] Khan, M. S., & Roberts, M. S. (2018). Challenges and innovations of drug delivery in older age. *Advanced drug delivery reviews*, 135, 3-38.
- [45] Khanbabaie, R., & Jahanshahi, M. (2012). Revolutionary impact of nanodrug delivery on neuroscience. *Current neuropharmacology*, 10(4), 370-392.

- [46] Kim, Y.-K. (2022). RNA therapy: rich history, various applications and unlimited future prospects. *Experimental & Molecular Medicine*, 54(4), 455-465.
- [47] Kumar, A., Pandey, A. N., & Jain, S. K. (2016). Nasal-nanotechnology: revolution for efficient therapeutics delivery. *Drug delivery*, 23(3), 671-683.
- [48] Lee, J. K., Alshehri, S., Kutbi, H. I., & Martin, J. R. (2015). Optimizing pharmacotherapy in elderly patients: the role of pharmacists. *Integrated Pharmacy Research and Practice*, 101-111.
- [49] Lees, P., Fink-Gremmels, J., & Toutain, P.-L. (2013). Veterinary pharmacology: history, current status and future prospects. *Journal of Veterinary Pharmacology and Therapeutics*, 36(2), 105-115.
- [50] Lewis, A. L., & Richard, J. (2015). Challenges in the delivery of peptide drugs: an industry perspective. *Therapeutic Delivery*, 6(2), 149-163.
- [51] Li, L. (2021). Deconstructing and historicizing access to medicines: The changing priority of pharmaceutical governance in China. *Frontiers in Sociology*, 5, 537919.
- [52] Li, N., Sun, C., Jiang, J., Wang, A., Wang, C., Shen, Y., . . . Zhao, X. (2021). Advances in controlled-release pesticide formulations with improved efficacy and targetability. *Journal of agricultural and food chemistry*, 69(43), 12579-12597.
- [53] Maduka, C. P., Adegoke, A. A., Okongwu, C. C., Enahoro, A., Osunlaja, O., & Ajogwu, A. E. (2023). REVIEW OF LABORATORY DIAGNOSTICS EVOLUTION IN NIGERIA'S RESPONSE TO COVID-19. *International Medical Science Research Journal*, 3(1), 1-23.
- [54] Maglalang, P. D., Rautiola, D., Siegel, R. A., Fine, J. M., Hanson, L. R., Coles, L. D., & Cloyd, J. C. (2018). Rescue therapies for seizure emergencies: new modes of administration. *Epilepsia*, 59, 207-215.
- [55] Mathias, N. R., & Hussain, M. A. (2010). Non-invasive systemic drug delivery: developability considerations for alternate routes of administration. *Journal of pharmaceutical sciences*, 99(1), 1-20.
- [56] Mendoza-Munoz, N., Urbán-Morlán, Z., Leyva-Gómez, G., de la Luz Zambrano-Zaragoza, M., & Quintanar-Guerrero, D. (2021). Solid lipid nanoparticles: an approach to improve oral drug delivery. *Journal of Pharmacy & Pharmaceutical Sciences*, 24, 509-532.
- [57] Merks, P., Jakubowska, M., Drelich, E., Świeczkowski, D., Bogusz, J., Bilmin, K., . . . Koziol, M. (2021). The legal extension of the role of pharmacists in light of the COVID-19 global pandemic. *Research in Social and Administrative Pharmacy*, 17(1), 1807-1812.
- [58] Milosavljevic, A., Aspden, T., & Harrison, J. (2018). Community pharmacist-led interventions and their impact on patients' medication adherence and other health outcomes: a systematic review. *International Journal of Pharmacy Practice*, 26(5), 387-397.
- [59] Mitchell, P., Wynia, M., Golden, R., McNellis, B., Okun, S., Webb, C. E., . . . Von Kohorn, I. (2012). Core principles & values of effective team-based health care. *NAM Perspectives*.
- [60] Mohiuddin, A. K. (2020). *The Role of the Pharmacist in Patient Care: Achieving High Quality, Cost-Effective and Accessible Healthcare through a Team-Based, Patient-Centered Approach*: Universal-Publishers.
- [61] Morgado, M. P., Morgado, S. R., Mendes, L. C., Pereira, L. J., & Castelo-Branco, M. (2011). Pharmacist interventions to enhance blood pressure control and adherence to antihypertensive therapy: review and meta-analysis. *American Journal of Health-System Pharmacy*, 68(3), 241-253.
- [62] Mossialos, E., Courtin, E., Naci, H., Benrimoj, S., Bouvy, M., Farris, K., . . . Sketris, I. (2015). From “retailers” to health care providers: transforming the role of community pharmacists in chronic disease management. *Health policy*, 119(5), 628-639.
- [63] Newman, S. P. (2005). Principles of metered-dose inhaler design. *Respiratory care*, 50(9), 1177-1190.
- [64] Odukoya, O. K., & Chui, M. A. (2013). E-prescribing: a focused review and new approach to addressing safety in pharmacies and primary care. *Research in Social and Administrative Pharmacy*, 9(6), 996-1003.
- [65] Okunade, B. A., Adediran, F. E., Maduka, C. P., & Adegoke, A. A. (2023). COMMUNITY-BASED MENTAL HEALTH INTERVENTIONS IN AFRICA: A REVIEW AND ITS IMPLICATIONS FOR US HEALTHCARE PRACTICES. *International Medical Science Research Journal*, 3(3), 68-91.
- [66] Osa, S. P., Chastain, D. B., & Young, H. N. (2022). Pharmacist role in addressing health disparities—Part 2: Strategies to move toward health equity. *Journal of the American College of Clinical Pharmacy*, 5(5), 541-550.

- [67] Owusu-Obeng, A., Weitzel, K. W., Hatton, R. C., Staley, B. J., Ashton, J., Cooper-Dehoff, R. M., & Johnson, J. A. (2014). Emerging roles for pharmacists in clinical implementation of pharmacogenomics. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, 34(10), 1102-1112.
- [68] Pan, S.-Y., Litscher, G., Gao, S.-H., Zhou, S.-F., Yu, Z.-L., Chen, H.-Q., . . . Ko, K.-M. (2014). Historical perspective of traditional indigenous medical practices: the current renaissance and conservation of herbal resources. *Evidence-based complementary and alternative medicine*, 2014.
- [69] Paranipe, M., & Müller-Goymann, C. C. (2014). Nanoparticle-mediated pulmonary drug delivery: a review. *International journal of molecular sciences*, 15(4), 5852-5873.
- [70] Paulino, E., Thomas, D., Lee, S. W. H., & Cooper, J. C. (2019). Dispensing process, medication reconciliation, patient counseling, and medication adherence. In *Clinical Pharmacy Education, Practice and Research* (pp. 109-120): Elsevier.
- [71] Peckham, A. M., Ball, J., Colvard, M. D., Dadiomov, D., Hill, L. G., Nichols, S. D., . . . Tran, T. H. (2021). Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic. *American Journal of Health-System Pharmacy*, 78(7), 613-618.
- [72] Peng, K., Vora, L. K., Tekko, I. A., Permana, A. D., Domínguez-Robles, J., Ramadon, D., . . . Donnelly, R. F. (2021). Dissolving microneedle patches loaded with amphotericin B microparticles for localised and sustained intradermal delivery: Potential for enhanced treatment of cutaneous fungal infections. *Journal of Controlled Release*, 339, 361-380.
- [73] Perez Cuevas, M. B., Kodani, M., Choi, Y., Joyce, J., O'Connor, S. M., Kamili, S., & Prausnitz, M. R. (2018). Hepatitis B vaccination using a dissolvable microneedle patch is immunogenic in mice and rhesus macaques. *Bioengineering & translational medicine*, 3(3), 186-196.
- [74] Pravin, S., & Sudhir, A. (2018). Integration of 3D printing with dosage forms: A new perspective for modern healthcare. *Biomedicine & Pharmacotherapy*, 107, 146-154.
- [75] Richter-Johnson, J., Kumar, P., Choonara, Y. E., du Toit, L. C., & Pillay, V. (2018). Therapeutic applications and pharmacoconomics of microneedle technology. *Expert review of pharmacoconomics & outcomes research*, 18(4), 359-369.
- [76] Roco, M., Bainbridge, W., Tonn, B., & Whitesides, G. (2013). Converging knowledge, technology, and society: Beyond convergence of nano-bio-info-cognitive technologies. *Dordrecht, Heidelberg, New York, London*, 450.
- [77] Roco, M. C. (2003). Nanotechnology: convergence with modern biology and medicine. *Current opinion in biotechnology*, 14(3), 337-346.
- [78] Rosenberg, M. (2010). Preparing for medical emergencies: the essential drugs and equipment for the dental office. *The Journal of the American Dental Association*, 141, S14-S19.
- [79] Rosenfeld, E., Kinney, S., Weiner, C., Newall, F., Williams, A., Cranswick, N., . . . Manias, E. (2018). Interdisciplinary medication decision making by pharmacists in pediatric hospital settings: an ethnographic study. *Research in Social and Administrative Pharmacy*, 14(3), 269-278.
- [80] Sakamoto, J. H., van de Ven, A. L., Godin, B., Blanco, E., Serda, R. E., Grattoni, A., . . . Ranganathan, S. I. (2010). Enabling individualized therapy through nanotechnology. *Pharmacological research*, 62(2), 57-89.
- [81] Sandler, N., & Preis, M. (2016). Printed drug-delivery systems for improved patient treatment. *Trends in pharmacological sciences*, 37(12), 1070-1080.
- [82] Schindel, T. J., Yuksel, N., Breault, R., Daniels, J., Varnhagen, S., & Hughes, C. A. (2017). Perceptions of pharmacists' roles in the era of expanding scopes of practice. *Research in Social and Administrative Pharmacy*, 13(1), 148-161.
- [83] Scott, T. O., Ewim, D. R., & Eloka-Eboka, A. C. (2022). Hybrid nanofluids flow and heat transfer in cavities: A technological review. *International Journal of Low-Carbon Technologies*, ctac093.
- [84] Seyhan, A. A., & Carini, C. (2019). Are innovation and new technologies in precision medicine paving a new era in patients centric care? *Journal of translational medicine*, 17, 1-28.
- [85] Signé, L. (2021). Strategies for effective health care for Africa in the fourth industrial revolution: bridging the gap between the promise and delivery.

- [86] Snoswell, C. L., Cossart, A. R., Chevalier, B., & Barras, M. (2022). Benefits, challenges and contributors to the introduction of new hospital-based outpatient clinic pharmacist positions. *Exploratory Research in Clinical and Social Pharmacy*, 5, 100119.
- [87] Streubel, A., Siepmann, J., & Bodmeier, R. (2006). Gastroretentive drug delivery systems. *Expert opinion on drug delivery*, 3(2), 217-233.
- [88] Sullivan, M. D., Sullivan, M., & Ballantyne, J. (2023). *The Right to Pain Relief and Other Deep Roots of the Opioid Epidemic*: Oxford University Press.
- [89] Tan, X., Feldman, S. R., Chang, J., & Balkrishnan, R. (2012). Topical drug delivery systems in dermatology: a review of patient adherence issues. *Expert opinion on drug delivery*, 9(10), 1263-1271.
- [90] Terry, P. D., & Dhand, R. (2023). 8 Nebulizers.
- [91] Tiwari, G., Tiwari, R., Sriwastawa, B., Bhati, L., Pandey, S., Pandey, P., & Bannerjee, S. K. (2012). Drug delivery systems: An updated review. *International journal of pharmaceutical investigation*, 2(1), 2.
- [92] Ummadi, S., Shrivani, B., Rao, N., Reddy, M. S., & Sanjeev, B. (2013). Overview on controlled release dosage form. *System*, 7(8), 51-60.
- [93] Upadhyay, G., Verma, S., Parvez, N., & Sharma, P. K. (2014). Recent trends in transdermal drug delivery system-a review. *Advances in biological research*, 8(3), 131-138.
- [94] van Mil, J. F., Schulz, M., & Tromp, T. F. D. (2004). Pharmaceutical care, European developments in concepts, implementation, teaching, and research: a review. *Pharmacy World and Science*, 26, 303-311.
- [95] Van Wijk, B. L., Klungel, O. H., Heerdink, E. R., & de Boer, A. (2005). Effectiveness of interventions by community pharmacists to improve patient adherence to chronic medication: a systematic review. *Annals of Pharmacotherapy*, 39(2), 319-328.
- [96] Wen, H., Jung, H., & Li, X. (2015). Drug delivery approaches in addressing clinical pharmacology-related issues: opportunities and challenges. *The AAPS journal*, 17, 1327-1340.
- [97] Yadav, K. S., Kapse-Mistry, S., Peters, G., & Mayur, Y. (2019). E-drug delivery: A futuristic approach. *Drug discovery today*, 24(4), 1023-1030.
- [98] Yu, X., Trase, I., Ren, M., Duval, K., Guo, X., & Chen, Z. (2016). Design of nanoparticle-based carriers for targeted drug delivery. *Journal of nanomaterials*, 2016.
- [99] Zellmer, W. A. (2001). The role of pharmacy organizations in transforming the profession: the case of pharmaceutical care. *Pharmacy in History*, 43(2/3), 75-85.
- [100] Zhang, Y., Zhang, H., Ghosh, D., & Williams III, R. O. (2020). Just how prevalent are peptide therapeutic products? A critical review. *International Journal of Pharmaceutics*, 587, 119491.
- [101] Zhang, Z., Ortiz, O., Goyal, R., & Kohn, J. (2014). Biodegradable polymers. *Handbook of polymer applications in medicine and medical devices*, 303-335.